The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.
April 22nd 2024
Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.
Therapeutic Advances in Plaque Psoriasis to Address Unmet Needs in Treatment and Improve Patient Outcomes
1.5 Credits / Dermatology
View More
Managed Care Considerations for Management of Molluscum Contagiosum: Examining Emerging Treatments
1.0 Credit / Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approaches and Raising Awareness of the Disease Burden
1.5 Credits / Dermatology
View More
Dose Reduction of Biologics to Treat Psoriasis Exhibits Inferior Efficacy to Normal Dose
February 12th 2020Dose reduction of biologics adalimumab, etanercept, and ustekinumab was not shown to be as effective as providing the usual doses for treatment of psoriasis, according to study findings published today.
Read More
Researchers Examine Short-term, Long-term Efficacy of Biologics, Oral Agents for Plaque Psoriasis
February 6th 2020In a meta-analysis comparison of biologics and oral treatments for moderate to severe plaque psoriasis, results suggest that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest response rates in both short-term and long-term therapy.
Read More
Researchers Distinguish IL-24 as Pivotal Mediator of Pro-inflammatory, Allergic Skin Diseases
January 29th 2020Researchers exhibit recent advances in the basic characteristics of interleukin (IL)-24, a member of the IL-20 family of cytokines associated with pro-inflammatory autoimmune disorders such as psoriasis, arthritis, and inflammatory bowel diseases, as a catalyst in the pathogenesis of allergic skin inflammation.
Read More
Calcipotriene, Betamethasone Dipropionate Cream Meets Phase 3 Trial Endpoints
January 24th 2020A formulation of calcipotriene and betamethasone dipropionate cream met its primary endpoint for treating plaque psoriasis during its phase 3 trial in the European Union, according to an announcement from MC2 Therapeutics.
Read More
Researchers Conduct Review of Interleukin-17 Controversies Across Medical Fields
January 15th 2020Researchers outlined a comprehensive review of the common mechanisms through which interleukin-17 (IL-17) is considered a molecular target for developing novel biological therapies in several different fields of medicine, according to report findings.
Read More
US Latino Population With Psoriasis Exposed to Heightened Disease Severity, Worse Quality of Life
January 9th 2020While prevalence rates of psoriasis are lower among the Latino population compared with the white and black populations in the United States, Latinos are shown to be disproportionately affected by poorer quality of life and intensified disease severity, according to study findings.
Read More
Janus Kinase Inhibitors Successfully Combat Psoriasis, Inflammatory Diseases, Review Finds
December 29th 2019A recently published review in Frontiers in Immunology highlights the efficacy of Janus kinase inhibitors as treatments for several dermatological ailments, including psoriasis. Authors described how newly researched pathologic factors have changed therapeutic practices used to treat inflammation and autoimmunity.
Read More
Bimekizumab Beats Adalimumab in Phase 3 Psoriasis Study
December 18th 2019The investigational therapy, an interleukin (IL)-17A and IL-17F inhibitor, is the third phase 3 study of bimekizumab to report positive results since October, following BE VIVID and BE READY, which evaluated the safety and efficacy of the drug.
Read More
Defective Stem Cell Behavior Linked to Psoriasis
December 14th 2019More treatments are needed for the 100 million individuals worldwide affected by psoriasis. Researchers from Brigham and Women's Hospital and the Harvard Stem Cell Institute have discovered a possible source of the skin thickening that may be triggered by dysregulated stem cells.
Read More
Development of PsA Linked to Tenosynovitis in Patients With Arthralgia
November 27th 2019Researchers used ultrasound to investigate the anatomical basis for arthralgia symptoms and found that tenosynovitis was the only significant difference in patients who went on to develop psoriatic arthritis (PsA).
Read More
Topline Results Announced for Second Phase 3 Trial of Bimekizumab
November 21st 2019BE READY is designed to evaluate the safety and efficacy of bimekizumab, humanized monoclonal IgG1 antibody that targets and neutralizes interleukin- (IL-)17A and IL-17F, a pair of cytokines that propel the inflammatory process through their effects on other messengers in the body that trigger chronic inflammatory response.
Read More
Providers Need to Heed Metabolic Syndrome's Complications for Women
November 15th 2019A recent study in the International Journal of Women’s Dermatology described the complex interplay of sex hormones in the pathways of metabolic syndrome (MetS) in pre- and postmenopausal women and how clinicians should be aware of the multiple factors of MetS.
Read More
Tildrakizumab More Cost-Effective Than Several Competitors in Treating Moderate to Severe Psoriasis
November 2nd 2019Authors led by Justin Carrico of RTI Health Solutions compared 9 different biologics and the oral drug apremilast in treatment of psoriasis; their anaylsis, “from a US health plan’s perspective,” involved both base cost and cost-effectiveness models that included adverse events.
Read More
Read More
The Use of Realized Prices and Real-World Outcomes Data in Assessments of Drug Value
Read More